Betta Investment Takes 9.9% Stake in C4 Therapeutics

TL;DR

**Betta Investment just bought a huge chunk of C4 Therapeutics, signaling big confidence!**

AI Summary

Betta Investment (Hong Kong) Ltd. has reported a significant stake in C4 Therapeutics, Inc., acquiring sole voting and dispositive power over 5,567,928 shares of common stock as of January 4, 2024. This represents a substantial 9.9% ownership of C4 Therapeutics, a biotechnology company. This matters to investors because a large institutional investment can signal confidence in the company's future prospects and potentially influence its stock price.

Why It Matters

A major new investor like Betta Investment (Hong Kong) Ltd. taking a nearly 10% stake can be seen as a vote of confidence, potentially attracting more investor interest and positively impacting C4 Therapeutics' stock valuation.

Risk Assessment

Risk Level: low — This filing indicates a new significant investor, which is generally a positive signal and lowers perceived risk for existing shareholders.

Analyst Insight

A smart investor would view this as a positive signal, potentially indicating a good entry point or reason to hold C4 Therapeutics stock, and might research Betta Investment's other holdings for similar investment theses.

Key Numbers

• 5,567,928 — Shares Beneficially Owned (Represents the total number of C4 Therapeutics shares Betta Investment (Hong Kong) Ltd. now controls.)
• 9.9% — Percentage of Class Owned (Indicates a significant ownership stake, giving Betta Investment a notable influence.)
• January 4, 2024 — Date of Event (The specific date when Betta Investment's ownership crossed the threshold requiring this disclosure.)

Key Players & Entities

• Betta Investment (Hong Kong) Ltd. (company) — the reporting person acquiring shares
• C4 Therapeutics, Inc. (company) — the subject company whose shares were acquired
• 5,567,928 (dollar_amount) — number of shares beneficially owned
• January 4, 2024 (person) — date of the event requiring the filing
• 9.9% (dollar_amount) — percentage of class beneficially owned

Forward-Looking Statements

• C4 Therapeutics' stock price may see a positive reaction due to increased institutional confidence. (C4 Therapeutics, Inc.) — medium confidence, target: Q1 2024
• Betta Investment (Hong Kong) Ltd. may seek to increase its stake or influence C4 Therapeutics' strategic decisions. (Betta Investment (Hong Kong) Ltd.) — low confidence, target: Next 12 months

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

• d636659dsc13g.htm (SC 13G) — 56KB
• d636659dex991.htm (EX-99.1) — 3KB
• 0001193125-24-007490.txt ( ) — 60KB

From the Filing

SC 13G 1 d636659dsc13g.htm SC 13G SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) January 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 12529R107 SCHEDULE 13G Page 2 of 7 Pages 1. NAMES OF REPORTING PERSONS Betta Investment (Hong Kong) Limited 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 5,567,928 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 5,567,928 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,567,928 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.1% (1) 12. TYPE OF REPORTING PERSON OO (1) The percentage of class was calculated based on 68,577,224 shares of Common Stock outstanding as of January 8, 2024, as reported by the Issuer to the Reporting Persons. CUSIP No. 12529R107 SCHEDULE 13G Page 3 of 7 Pages 1. NAMES OF REPORTING PERSONS Betta Pharmaceuticals Co., Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION China NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 5,567,928 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 5,567,928 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,567,928 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.1% (1) 12. TYPE OF REPORTING PERSON OO (1) The percentage of class was calculated based on 68,577,224 shares of Common Stock outstanding as of January 8, 2024, as reported by the Issuer to the Reporting Persons. CUSIP No. 12529R107 SCHEDULE 13G Page 4 of 7 Pages Item 1. Issuer (a) Name of Issuer: C4 Therapeutics, Inc. (the Issuer ) (b) Address of Issuers Principal Executive Offices: 490 Arsenal Way, Suite 120 Watertown, MA 02472 Item 2. Filing Person (a) (c) Name of Persons Filing; Address; Citizenship: (i) Betta Investment (Hong Kong) Limited, a limited company incorporated under the laws of Hong Kong ( Betta Investment ). (ii) Betta Pharmaceuticals Co., Ltd., a limited company incorporated under the laws of China ( Betta Pharma ). The address of the principal business office of each of the Reporting Persons is 355 Xingzhong Road, Linping, Hangzhou 311100, China. (d) Title of Class of Securities: Common Stock, par value $0.0001 per share (e) CUSIP Number: 12529R107 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: Not applicable. Item 4. (a) and (b) Amount beneficially owned: Betta Investment directly owns 5,567,928 shares of Common Stock, which represents approximately 8.1% of the outstanding shares of Common Stock. Betta Pharma, as the sole shareholder of Betta Investment, may be deemed to beneficially own the shares of Common Stock held directly by Betta Investment. (c) Number of shares as to which such person has: Number of Shares of Common Stock Reporting Person (i) (ii) (iii) (iv) Betta Investment 5,567,928 0 5,567,928 0 Betta Pharma 5,567,928 0 5,567,928 0 (i) Sole power to vote or direct the vote (ii) Shared power to vote or to direct the vote (iii) Sole power to dispose or to direct the disposition of (iv) Shared power to dispose or to direct the disposition of The percentage of class was calculated based on 68,577,224 shares of Common Stock outstanding as of January 8, 2024, as reported by the Issuer to the Reporting Persons. CUSIP No. 12529R107 SCHEDULE 13G Page 5 of 7 Pages Item 5. Not applicable.

View Full Filing

View this SC 13G filing on SEC EDGAR